Diamedica Inc (DMCAF) 0.0810 $DMCAF
DiaMedica to Expand Focus of DM199 Development into Acute Vascular Diseases
Marketwired - Mon Feb 02, 7:31AM CST
DiaMedica Inc. (TSX VENTURE: DMA) today, announced that the company will pursue the development of DM199, its recombinant form of the naturally occurring protein, tissue kallikrein-1 in acute vascular disease of the brain, kidney and heart. The primary focus will be on acute ischemic stroke and acute kidney injury indications.
DMA.VN: 0.095 (-0.005)
DiaMedica Announces Resignation of Mark Robbins, as Executive Vice President
Marketwired - Tue Jan 20, 7:15AM CST
DiaMedica Inc. (TSX VENTURE: DMA) announced today that Mark Robbins has resigned his position with the Company to pursue other opportunites. Mark joined DiaMedica as Vice President of Clinical and Regulatory and was named Executive Vice President in July 2014.
DMA.VN: 0.095 (-0.005)
DiaMedica Appoints David Gurvey as Vice President of Finance
Marketwired - Thu Jan 15, 7:04AM CST
DiaMedica Inc. (TSX VENTURE: DMA) today announced the appointment of Mr. David Gurvey as the Company's Vice President of Finance. Mr. Gurvey has more than 13 years of experience working with publicly traded and private companies in senior financial roles.
DMA.VN: 0.095 (-0.005)
DiaMedica Announces Restructuring
Marketwired - Tue Dec 09, 5:31PM CST
DiaMedica Inc. (TSX VENTURE: DMA) today announced a company-wide restructuring aimed at preserving cash, reducing operating costs and re-positioning the Company going forward.
DMA.VN: 0.095 (-0.005)
DiaMedica Announces Top-line Results of Phase IIa Clinical Trial of DM199 for Type 2 Diabetes
Marketwire Canada - Mon Nov 17, 7:00AM CST
DiaMedica Inc. (TSX VENTURE
MA) today announced top-line results of its Phase IIa proof of concept clinical trial of DM199 in patients with type 2 diabetes. DM199 is a recombinant form of the human tissue kallikrein-1 protein (rhKLK1).
DMA.VN: 0.095 (-0.005)
DiaMedica Publishes Manuscript Summarizing Preclinical Data on DM199 Treatment for Type 2 Diabetes
Marketwire - Thu Aug 07, 7:05AM CDT
DiaMedica Inc. (TSX VENTURE: DMA), a clinical stage biopharmaceutical company primarily focused on the development of novel, first-in-class therapies for metabolic disorders, kidney dysfunction and orphan diseases, today announced the publication of its manuscript entitled, "Preclinical Characterization of Recombinant Human Tissue Kallikrein-1 as a Novel Treatment for Type 2 Diabetes Mellitus," in PLOS ONE, an international, peer-reviewed, open access, scientific journal. The manuscript can be accessed at http://dx.plos.org/10.1371/journal.pone.0103981.
DMA.VN: 0.095 (-0.005)
DiaMedica to Present at InvestMNt Conference on August 6, 2014
Marketwire - Wed Jul 30, 7:03AM CDT
DiaMedica Inc. (TSX VENTURE: DMA), a clinical stage biopharmaceutical company primarily focused on the development of novel, first-in-class therapies for metabolic disorders, kidney dysfunction and orphan diseases, announced today that the Company will present at the 2014 InvestMNt conference sponsored by CFA Society Minnesota.
DMA.VN: 0.095 (-0.005)
DiaMedica Inc. Announces Results of Annual General and Special Meeting of Shareholders
Marketwire - Fri Jul 25, 3:30PM CDT
DiaMedica Inc. (TSX VENTURE: DMA), a clinical stage biopharmaceutical company primarily focused on the development of novel, first-in-class therapies for metabolic disorders, kidney dysfunction and orphan diseases, today announced that at its Annual General and Special Meeting (the "Meeting"
of shareholders held on July 24, 2014, Michael Giuffre, Rick Pauls, Richard Pilnik, Dawson Reimer and Thomas Wellner were re-elected as the Company's board of directors.
DMA.VN: 0.095 (-0.005)
DiaMedica Promotes Mark Robbins to Executive Vice President
Marketwire - Thu Jul 10, 7:31AM CDT
DiaMedica Inc. (TSX VENTURE: DMA), a clinical stage biopharmaceutical company focused on the treatment of diabetes and its complications, today announced the promotion of Mark Robbins, Ph.D., J.D., to Executive Vice President.
DMA.VN: 0.095 (-0.005)
DiaMedica Announces Stock Option Grant
Marketwire - Tue Jul 08, 4:10PM CDT
DiaMedica Inc. (TSX VENTURE: DMA), a clinical stage biopharmaceutical company focused on the treatment of diabetes and its complications, today announced a grant of 150,000 stock options to Richard Pilnik, the Company's newly appointed Chairman of the Board. The options were awarded in accordance with the Stock Option Plan at an exercise price of CAD $0.69 and a term of 10 years. The options are subject to acceptance by the TSX Venture Exchange.
DMA.VN: 0.095 (-0.005)
DiaMedica Appoints Rich Pilnik as Chairman of the Board of Directors
Marketwire - Mon Jul 07, 7:31AM CDT
DiaMedica Inc. (TSX VENTURE: DMA), a clinical stage biopharmaceutical company focused on the treatment of diabetes and its complications, announced today the appointment of Richard Pilnik as Chairman of the Company's Board of Directors.
LLY: 70.56 (+0.03), DMA.VN: 0.095 (-0.005)
DiaMedica to Expand Focus of DM199 Development into Acute Vascular Diseases
Marketwired - Mon Feb 02, 7:31AM CST
DiaMedica Inc. (TSX VENTURE: DMA) today, announced that the company will pursue the development of DM199, its recombinant form of the naturally occurring protein, tissue kallikrein-1 in acute vascular disease of the brain, kidney and heart. The primary focus will be on acute ischemic stroke and acute kidney injury indications.
DMA.VN: 0.095 (-0.005)
DiaMedica Announces Resignation of Mark Robbins, as Executive Vice President
Marketwired - Tue Jan 20, 7:15AM CST
DiaMedica Inc. (TSX VENTURE: DMA) announced today that Mark Robbins has resigned his position with the Company to pursue other opportunites. Mark joined DiaMedica as Vice President of Clinical and Regulatory and was named Executive Vice President in July 2014.
DMA.VN: 0.095 (-0.005)
DiaMedica Appoints David Gurvey as Vice President of Finance
Marketwired - Thu Jan 15, 7:04AM CST
DiaMedica Inc. (TSX VENTURE: DMA) today announced the appointment of Mr. David Gurvey as the Company's Vice President of Finance. Mr. Gurvey has more than 13 years of experience working with publicly traded and private companies in senior financial roles.
DMA.VN: 0.095 (-0.005)
DiaMedica Announces Restructuring
Marketwired - Tue Dec 09, 5:31PM CST
DiaMedica Inc. (TSX VENTURE: DMA) today announced a company-wide restructuring aimed at preserving cash, reducing operating costs and re-positioning the Company going forward.
DMA.VN: 0.095 (-0.005)
DiaMedica Announces Top-line Results of Phase IIa Clinical Trial of DM199 for Type 2 Diabetes
Marketwire Canada - Mon Nov 17, 7:00AM CST
DiaMedica Inc. (TSX VENTURE
MA) today announced top-line results of its Phase IIa proof of concept clinical trial of DM199 in patients with type 2 diabetes. DM199 is a recombinant form of the human tissue kallikrein-1 protein (rhKLK1). DMA.VN: 0.095 (-0.005)
DiaMedica Publishes Manuscript Summarizing Preclinical Data on DM199 Treatment for Type 2 Diabetes
Marketwire - Thu Aug 07, 7:05AM CDT
DiaMedica Inc. (TSX VENTURE: DMA), a clinical stage biopharmaceutical company primarily focused on the development of novel, first-in-class therapies for metabolic disorders, kidney dysfunction and orphan diseases, today announced the publication of its manuscript entitled, "Preclinical Characterization of Recombinant Human Tissue Kallikrein-1 as a Novel Treatment for Type 2 Diabetes Mellitus," in PLOS ONE, an international, peer-reviewed, open access, scientific journal. The manuscript can be accessed at http://dx.plos.org/10.1371/journal.pone.0103981.
DMA.VN: 0.095 (-0.005)
DiaMedica to Present at InvestMNt Conference on August 6, 2014
Marketwire - Wed Jul 30, 7:03AM CDT
DiaMedica Inc. (TSX VENTURE: DMA), a clinical stage biopharmaceutical company primarily focused on the development of novel, first-in-class therapies for metabolic disorders, kidney dysfunction and orphan diseases, announced today that the Company will present at the 2014 InvestMNt conference sponsored by CFA Society Minnesota.
DMA.VN: 0.095 (-0.005)
DiaMedica Inc. Announces Results of Annual General and Special Meeting of Shareholders
Marketwire - Fri Jul 25, 3:30PM CDT
DiaMedica Inc. (TSX VENTURE: DMA), a clinical stage biopharmaceutical company primarily focused on the development of novel, first-in-class therapies for metabolic disorders, kidney dysfunction and orphan diseases, today announced that at its Annual General and Special Meeting (the "Meeting"
of shareholders held on July 24, 2014, Michael Giuffre, Rick Pauls, Richard Pilnik, Dawson Reimer and Thomas Wellner were re-elected as the Company's board of directors. DMA.VN: 0.095 (-0.005)
DiaMedica Promotes Mark Robbins to Executive Vice President
Marketwire - Thu Jul 10, 7:31AM CDT
DiaMedica Inc. (TSX VENTURE: DMA), a clinical stage biopharmaceutical company focused on the treatment of diabetes and its complications, today announced the promotion of Mark Robbins, Ph.D., J.D., to Executive Vice President.
DMA.VN: 0.095 (-0.005)
DiaMedica Announces Stock Option Grant
Marketwire - Tue Jul 08, 4:10PM CDT
DiaMedica Inc. (TSX VENTURE: DMA), a clinical stage biopharmaceutical company focused on the treatment of diabetes and its complications, today announced a grant of 150,000 stock options to Richard Pilnik, the Company's newly appointed Chairman of the Board. The options were awarded in accordance with the Stock Option Plan at an exercise price of CAD $0.69 and a term of 10 years. The options are subject to acceptance by the TSX Venture Exchange.
DMA.VN: 0.095 (-0.005)
DiaMedica Appoints Rich Pilnik as Chairman of the Board of Directors
Marketwire - Mon Jul 07, 7:31AM CDT
DiaMedica Inc. (TSX VENTURE: DMA), a clinical stage biopharmaceutical company focused on the treatment of diabetes and its complications, announced today the appointment of Richard Pilnik as Chairman of the Company's Board of Directors.
LLY: 70.56 (+0.03), DMA.VN: 0.095 (-0.005)
